CVS Health (NYSE:CVS – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 7.900-8.100 for the period, compared to the consensus EPS estimate of 7.440. The company issued revenue guidance of $414.0M-, compared to the consensus revenue estimate of $409.2 billion.
CVS Health Stock Down 0.7%
CVS stock traded down $0.69 during mid-day trading on Friday, hitting $95.53. 5,037,505 shares of the company were exchanged, compared to its average volume of 8,451,642. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health has a 1-year low of $63.30 and a 1-year high of $110.68. The firm’s 50 day simple moving average is $102.17 and its 200 day simple moving average is $87.68. The firm has a market cap of $121.89 billion, a P/E ratio of 25.29, a P/E/G ratio of 0.90 and a beta of 0.61.
CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts predict that CVS Health will post 8 EPS for the current fiscal year.
CVS Health Dividend Announcement
Analysts Set New Price Targets
A number of research analysts recently issued reports on the company. Mizuho increased their price objective on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Cantor Fitzgerald raised their target price on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. boosted their price target on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Finally, Truist Financial raised their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and an average target price of $106.46.
Check Out Our Latest Research Report on CVS Health
Insider Activity at CVS Health
In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 3,372,000 shares of company stock valued at $317,473,598 in the last 90 days. 0.85% of the stock is owned by insiders.
Key Headlines Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS reported second-quarter adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.10 billion. Net income reached nearly $3 billion. CVS Health Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Adjusted EPS Outlook
- Positive Sentiment: Management raised its 2026 adjusted EPS outlook to $7.90–$8.10 and forecast at least $11.5 billion in operating cash flow, signaling confidence in earnings recovery and cash generation. CVS forecasts at least $11.5B in 2026 operating cash flow
- Positive Sentiment: Aetna’s Medicare Advantage turnaround and stronger retail performance supported the quarter, while an expanded collaboration with Eli Lilly gives CVS a role in the growing GLP-1 weight-management market. CVS Q2 Earnings Call Pairs Aetna Recovery With 2027 PBM Risks
- Neutral Sentiment: Analysts modestly increased CVS’s estimated fair value from $111.92 to $114.88, suggesting a constructive view, but continued execution and policy risks remain. CVS Health Stock Gets Fair Value Bump
- Negative Sentiment: Executives warned that Caremark membership is expected to decline in 2026, while changes affecting the 340B drug-pricing program could remain a headwind through 2027. These comments outweighed the immediate earnings beat and guidance increase, causing shares to reverse early gains and fall. One Comment on CVS’s Earnings Call Sent the Stock Tumbling
Institutional Investors Weigh In On CVS Health
Several hedge funds have recently bought and sold shares of CVS. Swiss RE Ltd. acquired a new position in shares of CVS Health in the fourth quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its stake in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares during the period. Mcguire Capital Advisors Inc. acquired a new position in CVS Health in the 4th quarter valued at $28,000. Kemnay Advisory Services Inc. bought a new position in CVS Health during the 4th quarter worth $40,000. Finally, Prosperity Bancshares Inc acquired a new stake in shares of CVS Health during the fourth quarter worth $43,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.
CVS Health Company Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
- Five stocks we like better than CVS Health
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
